Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities
31 mai 2017 11h38 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
15 mai 2017 17h23 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately...
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016
31 mars 2017 18h19 HE
|
Hemispherx Biopharma, Inc.
Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value Conference Call...
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017
06 mars 2017 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of...
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe
26 janv. 2017 10h51 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...
Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME
31 oct. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance Data presented at the 12th...
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone
19 oct. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it has completed its technology transfer of the Ampligen®...
Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
29 août 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it will present at CHI’s 4th Annual Immuno-Oncology...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
23 août 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 23, 2016 (GLOBE...
Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®
27 juil. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 27, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it has reached an agreement with Avrio Biopharmaceuticals...